Despite activism taking a hit this year, with the pandemic sending the markets into turmoil, Starboard Value has managed to find success at some of its targeted companies. The activist investor gained 17 seats on corporate boards through settlements and one shareholder vote by June 11, 2020, the highest total for the same period each year since records began in 2013.
After walking away from GCP Applied Technologies’ annual meeting with eight of 10 board seats at the end of last month, in Starboard’s first proxy contest to go to a vote since 2014, the activist turned its attention to settlement talks with Commvault Systems. The two were able to strike a deal, with the company agreeing to add three new directors to its board, including one previously advanced by Starboard, and create a new board committee.
The deal comes a little over two months since Starboard began a campaign to gain up to six seats at Commvault, including for its CEO Jeff Smith and Partner Gavin Molinelli.
What We’ll Be Watching For This Week
- Updates on the 22 key ESG metrics for consideration by boards being drafted by The World Economic Forum and the “big four” accounting firms.
- Will Shinei Bank shareholders vote Dalton Investments’ James Rosenwald onto the board or stick to the status quo at the meeting tomorrow?
- How will Dutch insurer NN Group respond to Elliott Management’s criticisms of the firm and the activist’s suggestions for improvement?
OSS Research Issues A Short Report Against Tactile Systems Technology
OSS Research issued a short report against Tactile Systems Technology last week, claiming the company’s revenue is dependent on “rampant overprescribing” and an ongoing Medicare investigation which the activist said could knock its stock down more than 70%. Tactile’s core business is pneumatic compression devices (PCDs) used to treat swelling in the legs and arms.
Among other claims, OSS argued that while Tactile Systems Technology has said the total addressable market (TAM) for PCDs is worth $5 billion and is growing at up to 30% annually, it is in fact closer to $300 million, citing “publicly available studies and claims databases.”
It also took exception to the company’s stated average revenue growth of 30% over the last five years. Citing “interviews with numerous industry stakeholders and a recent Qui Tam lawsuit filed against the company,” it said the “true source of Tactile Systems Technology’s growth was “a ‘daisy-chaining’ kick-back scheme that has resulted in rampant overprescribing and rapid market share gains at the expense of patients, insurers, and the public.” A “daisy chain” in this context is a phrase used to describe a group of investors who artificially inflate the price of a security they own so it can be sold at a profit. The short seller predicted that an industry-wide audit by Medicare was likely to result in a crackdown of “fraud and abuse.”
Chart Of The Week
The number of U.S-based companies operating in the energy sector publicly subjected to activist demands between January 01 and June 12 in consecutive years.
Original Article Posted at : https://www.valuewalk.com/2020/06/tactile-systems-technology-oss-research/<\p>